BR112017018964A2 - uso de plinabulin e métodos para tratar tumor cerebral - Google Patents
uso de plinabulin e métodos para tratar tumor cerebralInfo
- Publication number
- BR112017018964A2 BR112017018964A2 BR112017018964A BR112017018964A BR112017018964A2 BR 112017018964 A2 BR112017018964 A2 BR 112017018964A2 BR 112017018964 A BR112017018964 A BR 112017018964A BR 112017018964 A BR112017018964 A BR 112017018964A BR 112017018964 A2 BR112017018964 A2 BR 112017018964A2
- Authority
- BR
- Brazil
- Prior art keywords
- plinabulin
- methods
- brain tumor
- treat brain
- treat
- Prior art date
Links
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title abstract 3
- 229950011498 plinabulin Drugs 0.000 title abstract 3
- 208000003174 Brain Neoplasms Diseases 0.000 title abstract 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129623P | 2015-03-06 | 2015-03-06 | |
| US201562249807P | 2015-11-02 | 2015-11-02 | |
| PCT/US2016/020396 WO2016144636A1 (en) | 2015-03-06 | 2016-03-02 | Method of treating a brain tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017018964A2 true BR112017018964A2 (pt) | 2018-05-22 |
Family
ID=56880412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017018964A BR112017018964A2 (pt) | 2015-03-06 | 2016-03-02 | uso de plinabulin e métodos para tratar tumor cerebral |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10076518B2 (https=) |
| EP (1) | EP3265091A4 (https=) |
| JP (2) | JP6904570B2 (https=) |
| KR (1) | KR102623404B1 (https=) |
| CN (1) | CN107530340B (https=) |
| AU (2) | AU2016229295B2 (https=) |
| BR (1) | BR112017018964A2 (https=) |
| CL (1) | CL2017002242A1 (https=) |
| HK (1) | HK1249051A1 (https=) |
| IL (1) | IL254262A0 (https=) |
| MX (1) | MX385914B (https=) |
| MY (1) | MY194341A (https=) |
| RU (1) | RU2728796C2 (https=) |
| SG (1) | SG11201707128TA (https=) |
| WO (1) | WO2016144636A1 (https=) |
| ZA (1) | ZA201706035B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249051A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗脑肿瘤的方法 |
| MX383691B (es) * | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) * | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| KR20200112881A (ko) | 2018-01-24 | 2020-10-05 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법 |
| US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
| EP4093398B1 (en) * | 2020-01-22 | 2025-03-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Abt-751 and ionizing radiation for use in treating a brain tumor |
| US20230181499A1 (en) * | 2020-04-10 | 2023-06-15 | Lantern Pharma Inc. | Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer |
| KR20230130044A (ko) * | 2021-01-08 | 2023-09-11 | 랜턴 파마 인코포레이티드 | 일루딘 또는 하이드록시우레아메틸 아실풀벤을 사용한뇌 전이 및 cns 전이의 치료 |
| CA3215047A1 (en) | 2021-04-09 | 2022-10-13 | Lan Huang | Therapeutic compositions and methods for treating tumors |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
| CN120682197A (zh) * | 2024-03-19 | 2025-09-23 | 大连万春布林医药有限公司 | 普那布林的盐晶型 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS509164A (https=) | 1973-05-11 | 1975-01-30 | ||
| AU576322B2 (en) | 1983-07-22 | 1988-08-25 | Ici Australia Limited | Alpha-substituted-alpha-cyanomethyl alcohols |
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| JPS6411523A (en) | 1987-07-06 | 1989-01-17 | Kawashima Tekko Kk | Dish feeder in tableware washing machine |
| JPH059164A (ja) | 1991-07-02 | 1993-01-19 | Sumitomo Chem Co Ltd | 光学活性マンデロニトリル誘導体の製造方法 |
| GB9217331D0 (en) | 1992-08-14 | 1992-09-30 | Xenova Ltd | Pharmaceutical compounds |
| ES2224200T3 (es) | 1992-11-27 | 2005-03-01 | Mayne Pharma (Usa) Inc. | Composicion inyectable estable de paclitaxel. |
| JPH0725858A (ja) | 1993-07-13 | 1995-01-27 | Otsuka Pharmaceut Co Ltd | ピペラジン誘導体 |
| GB9402807D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9402809D0 (en) | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
| GB9426224D0 (en) | 1994-12-23 | 1995-02-22 | Xenova Ltd | Pharmaceutical compounds |
| US5891877A (en) | 1995-02-14 | 1999-04-06 | Xenova Limited | Pharmaceutical compounds |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| JP3131574B2 (ja) | 1996-09-04 | 2001-02-05 | 新日本製鐵株式会社 | 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤 |
| US5939098A (en) * | 1996-09-19 | 1999-08-17 | Schering Corporation | Cancer treatment with temozolomide |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| EP2201945B1 (en) | 1997-11-21 | 2013-03-06 | Purdue Neuroscience Company | Use of substituted 2-aminoacetamides for treating or ameliorating anxiety |
| PL342254A1 (en) | 1998-01-29 | 2001-06-04 | Aventis Pharm Prod Inc | Method of obtaining n-[(aliphatic or aromatic substituend)carbonyl)]-2-aminacetamide and cyclised compound |
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US6069146A (en) | 1998-03-25 | 2000-05-30 | The Regents Of The University Of California | Halimide, a cytotoxic marine natural product, and derivatives thereof |
| PL343249A1 (en) | 1998-03-26 | 2001-07-30 | Shionogi & Co | Indole derivatives with antiviral activity |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7026322B2 (en) | 1998-11-12 | 2006-04-11 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| US6358957B1 (en) | 1998-11-12 | 2002-03-19 | Nereus Pharmaceuticals, Inc. | Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds |
| EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| BRPI0017067B8 (pt) | 2000-01-18 | 2021-05-25 | Beyondspring Pharmaceuticals Inc | inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto |
| ATE417614T1 (de) | 2000-05-09 | 2009-01-15 | Angiorx Corp | Piperazindion-verbindungen |
| WO2002064592A1 (en) | 2000-12-28 | 2002-08-22 | Neurocrine Biosciences, Inc. | Tricyclic crf receptor antagonists |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7935704B2 (en) | 2003-08-01 | 2011-05-03 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| BR0313363A (pt) | 2002-08-02 | 2005-08-09 | Nereus Pharmaceuticals Inc | Deidrofenilahistinas e seus análogos, e sua sìntese |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| EP1711487A1 (en) * | 2004-02-04 | 2006-10-18 | Nereus Pharmaceuticals, Inc. | Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof |
| DE202004018940U1 (de) | 2004-12-07 | 2006-04-13 | Asf Verwaltungs Gmbh | Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| AU2007207465B2 (en) * | 2006-01-18 | 2012-12-06 | Merck Patent Gmbh | Specific therapy using integrin ligands for treating cancer |
| US8129527B2 (en) | 2006-11-03 | 2012-03-06 | Nereus Pharmacuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| US8449886B2 (en) | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| GB0907551D0 (en) | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| ES2543280T3 (es) | 2009-08-10 | 2015-08-17 | Board Of Regents, The University Of Texas System | Tratamiento de metástasis cerebrales con inhibidores de los receptores de endotelina en combinación con un agente quimioterapéutico citotóxico |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| EP2571577A1 (en) | 2010-05-17 | 2013-03-27 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
| US20130131018A1 (en) * | 2010-06-04 | 2013-05-23 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| JP2012033526A (ja) | 2010-07-28 | 2012-02-16 | Fuji Electric Co Ltd | 薄膜太陽電池およびその製造方法 |
| WO2012035436A1 (en) | 2010-09-15 | 2012-03-22 | Tokyo University Of Pharmacy And Life Sciences | Plinabulin prodrug analogs and therapeutic uses thereof |
| TWI386203B (zh) | 2011-01-07 | 2013-02-21 | Univ China Medical | 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| AU2013204313C1 (en) * | 2012-06-01 | 2016-04-07 | Bionomics Limited | Combination Therapy |
| WO2014160183A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
| EP2988668B1 (en) | 2013-04-24 | 2019-07-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Magnetic resonance maps for analyzing tissue |
| JP6411523B2 (ja) | 2013-10-11 | 2018-10-24 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| US9850225B2 (en) | 2014-04-14 | 2017-12-26 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| AU2016219204B2 (en) | 2015-02-12 | 2021-01-21 | Beyondspring Pharmaceuticals, Inc. | Use of Plinabulin in combination with immune checkpoint inhibitors |
| MX383691B (es) | 2015-03-06 | 2025-03-14 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
| HK1249051A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗脑肿瘤的方法 |
| US10155748B2 (en) | 2015-07-13 | 2018-12-18 | Beyondspring Pharmaceuticals, Inc. | Plinabulin compositions |
| WO2017139231A1 (en) | 2016-02-08 | 2017-08-17 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| RU2760348C2 (ru) | 2016-06-06 | 2021-11-24 | Бейондспринг Фармасьютикалс, Инк. | Способ уменьшения нейтропении |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| BR112019015974A2 (pt) | 2017-02-01 | 2020-03-31 | Beyondspring Pharmaceuticals, Inc. | Método para reduzir neutropenia |
| AU2018236168B2 (en) | 2017-03-13 | 2024-02-29 | Beyondspring Pharmaceuticals, Inc. | Compositions of plinabulin and use thereof |
-
2016
- 2016-03-02 HK HK18108933.3A patent/HK1249051A1/zh unknown
- 2016-03-02 SG SG11201707128TA patent/SG11201707128TA/en unknown
- 2016-03-02 MX MX2017011375A patent/MX385914B/es unknown
- 2016-03-02 KR KR1020177026283A patent/KR102623404B1/ko active Active
- 2016-03-02 CN CN201680020652.9A patent/CN107530340B/zh active Active
- 2016-03-02 RU RU2017131448A patent/RU2728796C2/ru active
- 2016-03-02 BR BR112017018964A patent/BR112017018964A2/pt not_active Application Discontinuation
- 2016-03-02 EP EP16762150.7A patent/EP3265091A4/en active Pending
- 2016-03-02 US US15/555,956 patent/US10076518B2/en active Active
- 2016-03-02 WO PCT/US2016/020396 patent/WO2016144636A1/en not_active Ceased
- 2016-03-02 AU AU2016229295A patent/AU2016229295B2/en active Active
- 2016-03-02 MY MYPI2017703256A patent/MY194341A/en unknown
- 2016-03-02 JP JP2017546767A patent/JP6904570B2/ja active Active
-
2017
- 2017-08-31 IL IL254262A patent/IL254262A0/en unknown
- 2017-09-04 CL CL2017002242A patent/CL2017002242A1/es unknown
- 2017-09-05 ZA ZA2017/06035A patent/ZA201706035B/en unknown
-
2018
- 2018-09-05 US US16/122,482 patent/US10357491B2/en active Active
-
2021
- 2021-02-22 JP JP2021026411A patent/JP7264331B2/ja active Active
- 2021-10-19 AU AU2021254549A patent/AU2021254549B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6904570B2 (ja) | 2021-07-21 |
| MY194341A (en) | 2022-11-29 |
| AU2016229295B2 (en) | 2021-11-04 |
| US20180042921A1 (en) | 2018-02-15 |
| CN107530340B (zh) | 2021-06-08 |
| JP2018507245A (ja) | 2018-03-15 |
| US20190000841A1 (en) | 2019-01-03 |
| HK1249051A1 (zh) | 2018-10-26 |
| MX2017011375A (es) | 2018-01-23 |
| JP7264331B2 (ja) | 2023-04-25 |
| SG11201707128TA (en) | 2017-09-28 |
| RU2017131448A3 (https=) | 2019-08-20 |
| AU2021254549B2 (en) | 2024-10-24 |
| KR20170123642A (ko) | 2017-11-08 |
| US10076518B2 (en) | 2018-09-18 |
| ZA201706035B (en) | 2019-12-18 |
| JP2021091695A (ja) | 2021-06-17 |
| RU2728796C2 (ru) | 2020-07-31 |
| EP3265091A4 (en) | 2018-08-01 |
| EP3265091A1 (en) | 2018-01-10 |
| CL2017002242A1 (es) | 2018-04-02 |
| CA2978679A1 (en) | 2016-09-15 |
| CN107530340A (zh) | 2018-01-02 |
| HK1250007A1 (zh) | 2018-11-23 |
| AU2016229295A1 (en) | 2017-09-28 |
| KR102623404B1 (ko) | 2024-01-11 |
| US10357491B2 (en) | 2019-07-23 |
| IL254262A0 (en) | 2017-10-31 |
| AU2021254549A1 (en) | 2021-11-18 |
| RU2017131448A (ru) | 2019-04-08 |
| MX385914B (es) | 2025-03-18 |
| WO2016144636A1 (en) | 2016-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| BR112018013731A2 (pt) | combinações anti-egfr para o tratamento de tumores | |
| MX2017015938A (es) | Inhibidores de ezh2 para el tratar linfomas. | |
| WO2016025635A3 (en) | Combination therapy for treating cancer | |
| MX364705B (es) | Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos. | |
| BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
| PT2958945T (pt) | Terapia de combinação envolvendo anticorpos contra claudina 18.2 para tratamento de cancro | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| IL270511A (en) | Combination therapies using niraparib and pembrolizumab for treating cancer | |
| EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
| LT3283527T (lt) | Kompleksinė terapija vėžio gydymui | |
| SV2017005373A (es) | Inhibidores de la proteína quinasa c y métodos de su uso | |
| MX373231B (es) | Agente anticancerigeno. | |
| BR112018013733A2 (pt) | combinações anti-cd20 para o tratamento de tumores a | |
| BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
| MX376193B (es) | Compuestos para tratar el cancer cerebral. | |
| WO2016043874A3 (en) | Combination therapy for treating cancer | |
| MX2015010791A (es) | Metodos para tratar el cancer y prevenir la resistencia a farmacos. | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| JOP20190056B1 (ar) | مركبات للاستخدام في علاج القصور الكلوي الحاد | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |